Press-release for stocks for sny

Prices are updated after-hours

FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
Published: 2021-03-04 (Crawled : 06:03) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M

| 1.03% | O: 1.21% H: 0.59% C: -0.24%
REGN | $898.33 -0.7% -0.71% 650K

| 102.52% | O: -0.3% H: 1.46% C: 0.9%
fda fda acceptance children dupixent

Sanofi launches recommended cash offer for all shares in Kiadis
Published: 2021-02-12 (Crawled : 06:03) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M

| -3.71% | O: -1.17% H: 1.08% C: 0.91%

49%

51%

KAVL | $6.275 135.02% 57.45% 44M

PXMD | $0.7375 79.09% 44.16% 4.5M

DYNT | $0.371 -5.12% 43.09% 3.3M

LGVN P | $2.94 73.96% 42.52% 57M

HUBC | $1.94 49.23% 32.99% 73M

SPCB | $0.4044 46.52% 31.75% 130M

ONVO | $1.34 32.66% 24.62% 54M

OMQS | $0.6869 32.1% 24.3% 3.6M

SNPO | $10.555 29.67% 22.88% 4M

AMBI | $3.72 -26.77% 21.77% 9.8K

Save your searches and get alerts when important news are released.